Show simple item record

dc.contributor.authorMoreno, L
dc.contributor.authorCaron, H
dc.contributor.authorGeoerger, B
dc.contributor.authorEggert, A
dc.contributor.authorSchleiermacher, G
dc.contributor.authorBrock, P
dc.contributor.authorValteau-Couanet, D
dc.contributor.authorChesler, L
dc.contributor.authorSchulte, JH
dc.contributor.authorDe Preter, K
dc.contributor.authorMolenaar, J
dc.contributor.authorSchramm, A
dc.contributor.authorEilers, M
dc.contributor.authorVan Maerken, T
dc.contributor.authorJohnsen, JI
dc.contributor.authorGarrett, M
dc.contributor.authorGeorge, SL
dc.contributor.authorTweddle, DA
dc.contributor.authorKogner, P
dc.contributor.authorBerthold, F
dc.contributor.authorKoster, J
dc.contributor.authorBarone, G
dc.contributor.authorTucker, ER
dc.contributor.authorMarshall, L
dc.contributor.authorHerold, R
dc.contributor.authorSterba, J
dc.contributor.authorNorga, K
dc.contributor.authorVassal, G
dc.contributor.authorPearson, AD
dc.date.accessioned2018-02-16T11:39:59Z
dc.date.issued2017-08
dc.identifier.citationExpert opinion on drug discovery, 2017, 12 (8), pp. 801 - 811
dc.identifier.issn1746-0441
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1194
dc.identifier.eissn1746-045X
dc.identifier.doi10.1080/17460441.2017.1340269
dc.description.abstractIntroduction Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively small numbers of patients. Areas covered: The current drug development model has been slow, associated with significant attrition, and few new drugs have been developed for neuroblastoma. The Neuroblastoma New Drug Development Strategy (NDDS) has: 1) established a group with expertise in drug development; 2) prioritised targets and drugs according to tumour biology (target expression, dependency, pre-clinical data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3) promoted clinical trials with target-prioritised drugs. Drugs showing activity can be rapidly transitioned via parallel randomised trials into front-line studies. Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.
dc.formatPrint-Electronic
dc.format.extent801 - 811
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectNeuroblastoma
dc.subjectAntineoplastic Agents
dc.subjectPrognosis
dc.subjectDrug Evaluation, Preclinical
dc.subjectDrug Design
dc.subjectTime Factors
dc.subjectAdolescent
dc.subjectChild
dc.subjectRandomized Controlled Trials as Topic
dc.subjectMolecular Targeted Therapy
dc.titleAccelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/17460441.2017.1340269
rioxxterms.licenseref.startdate2017-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfExpert opinion on drug discovery
pubs.issue8
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume12
pubs.embargo.termsNot known
icr.researchteamPaediatric Solid Tumour Biology and Therapeuticsen_US
dc.contributor.icrauthorChesler, Louisen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record